Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinerof cream.
NEW ORLEANS — Symptoms of prurigo nodularis were significantly improved after 16 weeks of monotherapy with nemolizumab, according to a presenter at the American Academy of Dermatology Annual Meeting.“Prurigo nodularis, PN, is characterized by these intensely itchy nodules that are commonly on the extremities and the trunk,” Shawn G. Kwatra, MD, associate professor of dermatology
(0)
- Approximately One in Five Tapinarof Patients Achieved At Least 90% Disease Clearance -
- A Significantly Higher Portion of Psoriasis Patients Experienced Clinically Meaningful Improvements in Itch with Tapinarof Compared to Vehicle -
- Improvements in DLQI Exceeded MCID at Week 12 with Statistical Significance Compared to Vehicle -
- Data Will Be Included in NDA Submission for Tapinarof, Expected Mid-2021 -
Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, will present data from its two pivotal Phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 (tapinarof 1%, n=340; vehicle, n=170) and PSOARING 2 (tapinarof 1%, n=343; vehicle, n=172), at the American Academy of Dermatology Virtual Meeting Experience 2021 (AAD VMX 2021) on April 23-25, 2021.
Dermavant to Showcase PASI90, Itch and Quality of Life Data from Phase 3 Pivotal Trials for Tapinarof at AAD VMX 2021 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.